<DOC>
	<DOCNO>NCT00435981</DOCNO>
	<brief_summary>This randomize , placebo-controlled phase II study investigate prime boost 20ug Diamyd® ( rhGAD65 formulate Alhydrogel® ) , administer subcutaneously four week apart , safe preserve beta cell function child adolescent type 1 diabetes diabetes duration le 18 month intervention .</brief_summary>
	<brief_title>Efficacy Safety Diamyd® Children Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Key Male female patient 10 18 year age , diagnose type 1 diabetes within 18 month Fasting Cpeptide level 0.1 nmol/l Presence GAD65 antibody Written inform consent ( patient parent/guardian ) Key Secondary diabetes mellitus MODY Treatment immunosuppressant Treatment vaccine within 1 month prior first Diamyd® dose plan treatment vaccine 2 month second Diamyd® dose Participation clinical trial new chemical entity within previous 3 month History certain disease condition ( e.g . epilepsy , anaemia , alcohole drug abuse ) HIV hepatitis Presence associate serious disease condition opinion investigator make patient noneligible study Pregnancy ( plan pregnancy within one year 2nd administration )</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>GAD65</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>C-peptide</keyword>
	<keyword>Children</keyword>
</DOC>